CN115915971A - 抗肥胖用组合物 - Google Patents
抗肥胖用组合物 Download PDFInfo
- Publication number
- CN115915971A CN115915971A CN202180042423.8A CN202180042423A CN115915971A CN 115915971 A CN115915971 A CN 115915971A CN 202180042423 A CN202180042423 A CN 202180042423A CN 115915971 A CN115915971 A CN 115915971A
- Authority
- CN
- China
- Prior art keywords
- obesity
- group
- present
- extract
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000003579 anti-obesity Effects 0.000 title description 4
- 208000008589 Obesity Diseases 0.000 claims abstract description 62
- 235000020824 obesity Nutrition 0.000 claims abstract description 62
- 239000000284 extract Substances 0.000 claims description 38
- 238000000605 extraction Methods 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 16
- 241000382455 Angelica sinensis Species 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000018823 dietary intake Nutrition 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 241001192908 Phlomis umbrosa Species 0.000 claims description 8
- 239000000287 crude extract Substances 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 208000007882 Gastritis Diseases 0.000 claims description 4
- 108010068370 Glutens Proteins 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 4
- 235000021312 gluten Nutrition 0.000 claims description 4
- 230000001272 neurogenic effect Effects 0.000 claims description 4
- 241000544270 Angelica acutiloba Species 0.000 claims description 3
- 241000028057 Cynanchum auriculatum Species 0.000 claims 2
- 235000019197 fats Nutrition 0.000 description 21
- 235000009200 high fat diet Nutrition 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 244000061520 Angelica archangelica Species 0.000 description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- -1 maltose and sucrose Chemical compound 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 240000001810 Angelica gigas Species 0.000 description 6
- 235000018865 Angelica gigas Nutrition 0.000 description 6
- 241000068415 Cynanchum bungei Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000000579 abdominal fat Anatomy 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000612118 Samolus valerandi Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241000208173 Apiaceae Species 0.000 description 3
- 229930185597 Euphorbia lathyris Natural products 0.000 description 3
- 241001553700 Euphorbia lathyris Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- 235000004348 Perilla frutescens Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000331432 Cynanchum wilfordii Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001063197 Ostericum grosseserratum Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 241001303775 Phlomis Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000519999 Stachys Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000107360 Vincetoxicum glaucescens Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000001930 leg bone Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/08—Alcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及用于预防、改善或治疗肥胖的组合物。
Description
【技术领域】
本专利申请要求于2020年6月5日向韩国专利局提交的韩国专利第10-2020-0068218号的优选权,该专利申请的全部内容在此引入本申请作为参考。
本发明涉及用于预防、改善或治疗肥胖的组合物。
【背景技术】
现代人接触的饮食文化不仅是生活环境的提高和追求便利的快餐食品的增加,饮食生活的西化而急剧增加了单糖、肉类、脂肪等的摄入,而且由于繁忙的社会生活中承受的压力和缺乏运动、食物摄入过多等原因,肥胖患者日益增多。这导致各种慢性成人疾病的患率增加,从综合流行病学研究来看,这些疾病与肥胖有非常密切的关系。此外,最近为了预防及治疗在社会和经济上出现的严重性的成人病,需要提出改善或治疗肥胖的开创性方法。
肥胖是由于从食物中摄取的能量与身体活动消耗的能量之间的不平衡,过剩的能量以身体脂肪的形式积累的现象。通常,肥胖是指体内脂肪组织过多的状态,当这种肥胖状态长期持续时,会引发糖尿病、高脂血症、心脏病、中风、动脉硬化症、脂肪肝等各种代谢性疾病和成人病。肥胖的主要发生原因是过剩的能量供应引起脂肪细胞大小和数量的增加,从而积累到体内脂肪,此外还有遗传因素、西化饮食引起的环境因素、心里因素、能量代谢异常等多种原因。
肥胖是由于热量摄入和消耗失衡引起的一种代谢性疾病,体内积累的脂肪远远超过脂肪组织功能所需要的脂肪量,这导致人体内正常的生化和生理功能产生障碍。不仅是身体活动的不便、工作效率的降低、身体发育的变相增长,还会引起糖尿病、高脂血症、血液胆固醇升高、肾脏疾病、中风、脂肪肝及冠状动脉疾病以及关节疾病等多种疾病。在过去的几十年里,随着肥胖发生率的迅速增加,人们对肥胖的关注度不断提高,认识到肥胖的原因是由破坏能量平衡的环境因素的综合因素所决定,而不是单纯的遗传原因。
脂肪细胞在体内的功能是蓄积身体所需能量,必要时通过分解中性脂肪来利用。脂肪组织不仅有蓄积能量的功能,还作为内分泌器官,在体内执行调节能量代谢的功能,包括脂肪代谢、糖代谢。并且,脂肪细胞通过前脂肪细胞(Preadipocyte)从间充质前体细胞(Mesenchymal precursor)分化为脂肪细胞,在分化过程中通过形态学和生化变化积累体内脂肪,脂肪组织由大小增加、新的脂肪细胞分化而成。这种脂肪细胞的大小一般可以通过控制饮食来实现,但新的前脂脂肪细胞向脂肪细胞分化的过程并不能通过控制饮食来发挥作用,因此,为了从根本上治疗或抑制肥胖,控制脂肪的分化过程是至关重要。
治疗这种肥胖的目的大致可分为两大类。第一是通过燃烧过量的脂肪来减重,第二是改善代谢性失衡。目前肥胖的治疗目的不仅在于减重,还在于早期去除导致心血管疾病的因素来改善代谢异常。并且,正在积极开展通过控制饮食摄入量及能量消耗来抑制肥胖的研究。
目前已知的治疗肥胖的药物按作用机理大体分为饱腹感增强剂、脂肪吸收抑制剂、抗精神病类食欲抑制剂,其中最具代表性的药物有赛尼可(Xenical,罗氏制药公司,瑞士)、诺美亭(Reductil,爱博特公司,美国)、Exolise(艾蔻法,法国)等,但会引起脂肪泻、肠气、腹胀、大便失禁等,并伴有心脏病、呼吸系统疾病及神经系统疾病等副作用,从而具有疗效持续性低等问题。
据此,为了尽量减少上述人工合成物质的副作用,迫切需要从天然物质中开发出有效控制体重的功能材料。
【发明内容】
【技术问题】
为此,本发明人致力寻找一种在抑制肥胖方面表现优异的天然物质,结果,通过动物模型实验获得的组织分析鉴定一种有效预防、改善及治疗肥胖的组合物。
本发明的目的在于,提供用于预防或改善肥胖的食品组合物。
本发明的另一目的在于,提供用于预防或治疗肥胖的药物组合物。
【技术方案】
本发明涉及用于预防、改善或治疗肥胖的组合物。
以下,更详细地说明本发明。
本发明的一例涉及包含选自由白首乌、糙苏及当归组成的组中的一种以上提取物的用于预防或改善肥胖的食品组合物。
在本发明中,肥胖可以为饮食摄取引起的肥胖、神经性胃炎性肥胖、麸质过度肥胖、静脉循环障碍肥胖或代谢性肥胖,但并不限定于此。
在本发明中,代谢性肥胖可以引起糖尿病、高脂血症、心脏病、中风、动脉硬化症或脂肪肝,但并不限定于此。
白首乌也称为白何首乌,作为原产植物的隔山消是一种称为“牛皮消”的萝藦科植物,生长在山脚下向阳的草地或海边斜坡。秋季至冬季采收根部,晒干后入药。白首乌味甘微苦,性微温。在韩医方面,此药补肝强筋骨,促进消化,具有解毒功能。利用这些功效,可用于肝肾虚、阳痿、遗精、腰膝酸软、脾虚不运、脘腹胀满、腹泻、白发长得比年龄快、产后缺乳等。
糙苏是唇形科多年生草本植物,学名为Phlomis umbrosa TURCZ.。作为韩药材之一,原为野兔花的干燥根,现野兔花稀少,改用唇形科的糙苏代用。之所以命名为糙苏,是因为擅长治疗骨折。成分包含生物碱、精油、维生素E等。药性温和,味苦。对肝肾功能衰弱引起的腰痛和腿部骨骼及肌肉运动不良有效。对关节炎或风湿病也有效,常用于治疗椎间盘突出和背部瘀伤。对女性来说,孕期服用可防止流产,月经过多或子宫大出血时也有止血作用。对老年人来说,多用于下肢无力而具有步态障碍或屈伸不畅引起的麻木疼痛。最好避免与生地黄同用,也不用于痢疾。典型的处方有续断丸。幼芽也可以当野菜吃。
当归在韩国指的是伞形科朝鲜当归(Angelica gigas Nakai)的干燥根,在中国指的是伞形科中国当归(Angelica sinensis(Oliv.)Diels)的干燥根。在日本,将伞形科东当归(Angelica acutiloba(Siebold.&Zucc.)Kitag.)或北海道当归(Angelica acutiloba(Siebold.&Zucc.)Kitag.Var.sugiyamae Hikino)的根晒干使用。据说,“当归”这个名字是附加了想要归来的意思。这源于很久以前中国的一个风俗,妇人惦记着上战场的丈夫,往怀里塞当归,因为人们相信在战场上精力耗尽的时候,吃当归就能重新恢复元气。另一种说法是“服此药,气血归原”而得名。此药材性温、味甘辛,一般朝鲜当归相对于中国当归或东当归甜味弱,辛味重。当归的功效主要是在血液不足时起到补血的作用。用中国当归或东当归的根制成的当归有很好的补血作用。但是,由朝鲜当归的根制成的当归助于血循环的活血作用优于补血作用,具有很强的抗癌和降压作用。在药理学上,当归促进冠状动脉血流量,刺激红细胞生成。朝鲜当归也被称为土当归、当归草、野当归,中国当归也被称为当归、文归、乾归、大芹、象马、地仙丸、东当归也被称为日当归。
在本发明中,组合物可包含选自由白首乌、糙苏及当归组成的组中的一种以上提取物,例如,可包含白首乌、糙苏及当归的混合提取物或白首乌提取物、糙苏提取物及当归提取物的混合物。
在本发明中,白首乌提取物可以是使用选自由其根、茎及叶组成的组中的一种以上制备的提取物,例如,可以使用根制备,但并不限定于此。
在本发明中,糙苏提取物可以是使用选自由其根、茎及叶组成的组中的一种以上制备的提取物,例如,可以使用根制备,但并不限定于此。
在本发明中,当归提取物可以是使用选自由其根,茎及叶组成的组中的一种以上制备的提取物,例如,可以使用根制备,但并不限定于此。
本发明的提取物可以是用选自由水及碳原子数为1个至4个的直链或支链醇组成的组中的一种以上溶剂提取得到的粗提取物,例如,可以是以水为溶剂提取得到的粗提取物。
在用于制备本发明的粗提取物的一种溶剂中使用水和醇的混合物时,可以为10%(v/v)以上至小于100%(v/v)、20%(v/v)以上至小于100%(v/v)、30%(v/v)以上至小于100%(v/v)、40%(v/v)以上至小于100%(v/v)、50%(v/v)以上至小于100%(v/v)、60%(v/v)以上至小于100%(v/v)、或70%(v/v)以上至小于100%(v/v)的碳原子数为1个至4个的直链或支链醇水溶液。
在本发明中,醇水溶液可以为选自由甲醇水溶液、乙醇水溶液、丙醇水溶液及丁醇水溶液组成的组中的一种以上,但并不限定于此。
本发明的提取物可以是将溶剂粗提取物由额外的溶剂分馏的溶剂分馏物。
本发明的组合物中作为有效成分的提取物的含量可根据使用形式及目的、患者情况、症状种类及轻重等进行适当调整,例如,以固体成分重量为基准,其可以为0.001重量百分比至99.9重量百分比、0.1重量百分比至99.9重量百分比,优选地,0.1重量百分比至50重量百分比、0.1重量百分比至40重量百分比,但并不限定于此。
以下,对本发明的提取物的制备过程更详细地进行描述。
切割选自由白首乌、糙苏及当归组成的组中的一种以上,用水洗涤以去除杂物并干燥,然后对选自由上述白首乌、糙苏及当归组成的组中的一种以上用其重量的约5倍至20倍体积,优选地,7倍至15倍体积的提取溶剂进行回流提取。提取后,进行过滤收集滤液。提取温度没有特别限定,但优选为40℃至110℃,更优选为55℃至105℃。
提取工艺可以重复一次或多次,在本发明的优选实施例中,可以采用第一次提取后再次提取的方法,这是为了防止如下的问题,在大量生产生药提取物时,即使进行有效过滤,但由于生药本身水分含量高,会造成损失,如果仅进行第一次提取,提取效率会下降。并且,对各阶段的提取效率进行验证,结果表明通过第二次提取可提取整体提取量的80%至90%左右。
在本发明中,当提取工艺重复两次时,对上述获得的残渣用提取溶剂的约5倍至15倍体积,优选地,8倍至12倍体积进行回流提取。提取后进行过滤并与先前获得的滤液合并,并通过减压浓缩来制备提取物。
如上所述,可通过混合两次提取及每次提取后的滤液来提高提取效率,但本发明的提取物并不限于提取次数。
如果制备本发明的提取物所用溶剂的量过少,则难以搅拌,提取物的溶解度降低,导致提取效率下降,如果过多,则导致在下一步纯化步骤中使用的溶剂的使用量增加,变得不经济并且可导致操作上的问题,因此溶剂的使用量最好在上述范围内。
为了控制残余的低级醇的含量,以将如上所述得到的过滤提取物适于用作药品或食品原料,用浓缩物总量的约10倍至30倍,优选地,15倍至25倍,更优选地,约20倍的水共沸浓缩1次至5次,优选地,2次至3次,再加入等量的水悬浮均匀,然后冷冻干燥和/或喷雾干燥,制成粉末状态的提取物。
在本发明中,组合物可通过各种途径给药到包括人在内的哺乳动物。给药方式可以是任何常用的方式,例如,通过口服、皮肤、静脉、肌肉、皮下等途径给药,优选地,可以口服给药。
在本发明中,食品组合物可以是各种食品、饮料、食品添加剂等。
根据食品的形态、所需用途等,适当选择上述食品组合物中含有的作为有效成分的生药提取物的含量,没有特别限定,例如,可以按照食品总重量的0.01重量百分比至15重量百分比进行添加,对于健康饮料组合物,以100ml为基准,可按照0.02g至10g,优选地,0.3g至1g的比率进行添加。
在本发明中,饮料组合物除了包含指定比例的上述提取物作为必需成分之外,对液体成分没有特别限制,像常规饮料一样,可包含各种香味剂或天然碳水化合物作为附加成分。
上述天然碳水化合物是常见糖类及糖醇,上述常见糖类为单糖,例如葡萄糖、果糖等、双糖,例如麦芽糖、蔗糖等、以及多糖,例如糊精、环糊精,上述糖醇为木糖醇、山梨糖醇、赤藓糖醇等。
作为除上述以外的香味剂,可以有利地使用天然香味剂(奇异果甜蛋白、甜叶菊提取物(例如,莱鲍迪苷A、甘草甜素等))和合成香味剂(糖精、阿斯巴甜等)。上述天然碳水化合物的比率为每100ml本发明的组合物一般约1g至20g,优选地,约5g至12g。
除上述外,本发明的组合物可包含各种营养素、维生素、矿物质(电解质)、如合成风味剂及天然风味剂等风味剂、着色剂及填充剂(奶酪、巧克力等)、果胶酸及其盐、海藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、醇类、碳酸饮料中使用的碳酸化剂等。此外,本发明的组合物可包含用于制备天然果汁、果汁饮料及蔬菜饮料的果肉。这种成分可以单独或组合来使用。这种添加剂的比率并不重要,但一般选自每100重量份的本发明的组合物0重量份至约20重量份的范围。
尤其,将本发明的提取物给药到人体时,考虑到天然提取物的一般特性,与其他合成药品相比,可以避免副作用,实际上,对规范化的生药组合物的毒性试验结果表明,对生物体没有任何影响。
本发明的另一例涉及包含选自由白首乌、糙苏及当归组成的组中的一种以上提取物的用于预防或治疗肥胖的药物组合物。
在本发明中,上述肥胖可以为饮食摄取引起的肥胖、神经性胃炎性肥胖、麸质过度肥胖、静脉循环障碍肥胖或代谢性肥胖,但并不限定于此。
在本发明中,上述代谢性肥胖可以引起糖尿病、高脂血症、心脏病、中风、动脉硬化症或脂肪肝,但并不限定于此。
在本发明中,上述提取物是用选自由水及碳原子数为1个至4个的直链或支链醇组成的组中的一种以上溶剂提取得到的粗提取物,但并不限定于此。
上述提取物与上述相同,因此将省略其记载。
在本发明中,组合物可通过各种途径给药到包括人在内的哺乳动物。给药方式可以是任何常用的方式,例如,通过口服、皮肤、静脉、肌肉、皮下等途径给药,优选地,可以口服给药。
在本发明中,组合物可分别按常规方法剂型化使用,如散剂、颗粒剂、片剂、胶囊剂、软膏剂、混悬剂、乳剂、糖浆、气雾剂等口服剂型或透皮制剂,栓剂及灭菌注射溶液形式的肠胃外剂型。
在本发明中,除上述混合提取物外,组合物可包含药学上和生理学上可接受的载体、赋形剂和稀释剂等辅料。
在本发明中,可包含在组合物中的载体、赋形剂和稀释剂包括乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖醇、木糖醇、赤藓糖醇、麦芽糖醇、淀粉、阿拉伯树胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石粉、硬脂酸镁和矿物油。
在制剂化的情况下,可以使用稀释剂或赋形剂,例如常用的填充剂、增量剂、粘合剂、润湿剂、崩解剂和表面活性剂等。口服固体制剂包括片剂、丸剂、散剂、颗粒剂、胶囊剂等,这种固体制剂至少含有一种赋形剂,如淀粉、碳酸钙(calcium carbonate)、蔗糖(sucrose)或乳糖(lactose)、明胶等。并且,除了简单的赋形剂外,还使用硬脂酸镁、滑石粉等润滑剂。
口服制剂包括混悬剂、内服溶液剂、乳剂、糖浆剂、软膏剂等,除作为常用的单纯稀释剂的水和液体石蜡外,还可以包括各种赋形剂,如润湿剂、甜味剂、芳香剂、防腐剂等。
肠胃外制剂包括灭菌水溶液、非水溶剂、混悬剂、乳剂、冻干制剂、栓剂、透皮制剂等。作为非水溶剂、混悬剂可使用丙二醇、聚乙二醇、橄榄油等植物油、油酸乙酯等可注射酯等。
作为栓剂可以使用合成脂肪酸酯(witepsol)、聚乙二醇、吐温(tween)61、可可脂、月桂脂、甘油明胶等。
在将本发明的组合物应用于人的具体例中,本发明的组合物可以单独给药,但一般考虑到给药方式和标准制药实践(standard phamaceutical practice),可以与选定的药物载体混合给药。
例如,本发明的组合物可以以包含淀粉或乳糖的片剂形式,或者赋形剂单独或包含赋形剂的胶囊形式,或者包含调味或着色的化学药品的酏剂或悬浮剂形式口服、口腔内或舌下注射。这种液体制剂可以与药学上可接收的添加剂,如悬浮剂(例如,半合成甘油酯,如甲基纤维素、合成脂肪酸酯(witepsol);或者甘油酯混合物,如杏仁油(apricot kerneloil)和PEG-6酯的混合物、或PEG-8和辛酸/癸酸甘油酯的混合物)一同制备而成。
本发明的组合物的剂量可根据患者的年龄、体重、性别、给药形式、健康状态及患病程度而变化,也可以根据医生或药师的判断,每隔一段时间,每天给药一次至数次。例如,以有效成分含量为基准,日剂量可以为0.1mg/kg至500mg/kg,优选地,0.5mg/kg至300mg/kg。上述剂量为平均情况的示例,可根据个人差异,其剂量可更高或更低。
如果本发明的组合物的每日剂量小于上述剂量,则不能获得显著效果,如果超过该剂量,则不仅不经济而且超出了通常剂量的范围,因此,有可能出现不可取的副作用,因此以上述范围为宜。
本发明所使用的提取方法可以是任何通常使用的方法,例如可以为冷泡法、热水提取法、超声波提取法或回流冷却提取法,例如,可以是热水提取法,但并不限定于此。
【发明的效果】
本发明涉及用于预防、改善或治疗肥胖的组合物,本发明的组合物可用作对肥胖的预防、改善或治疗有用的组合物。
【附图说明】
图1a为示出根据本发明一实施例的血清中总胆固醇浓度测定结果的图表。
图1b为示出根据本发明一实施例的血清中中性脂肪浓度测定结果的图表。
图2a为示出根据本发明一实施例的腹部脂肪组织量测定结果的图表。
图2b为示出根据本发明一实施例的肾脏周围脂肪重量测定结果的图表。
图3为示出根据本发明一实施例的中性脂肪合成相关蛋白质的表达水平测定结果的照片。
【具体实施方式】
本发明涉及包含选自由白首乌、糙苏及当归组成的组中的一种以上提取物的用于预防或改善肥胖的食品组合物。
【发明的实施方式】
以下,通过下述实施例更详细地说明本发明。但是这些实施例仅用于例示本发明,而本发明的范围并不限定于这些实施例。
【实施例1.粗提取物的制备】
将作为天然生药材的白首乌(Cynanchum wilfordii)根、糙苏(Phlomis umbrosa)根及朝鲜当归(Angelica gigas)根按1:1:1.08的重量比混合,然后加入10倍量的水在95℃至105℃的温度下加热及提取8小时。接着,经过过滤,将过滤后的滤液在-80℃下冷冻干燥,获得粉末形式的粗提取物。
【实验例1.提取物对肥胖诱导小鼠的功效评价】
【1-1.实验动物及饲养环境的准备】
购买出生5周龄的雄性C57BL/J小鼠(Samtaco Bio Korea,Ltd.),在动物饲养室以规定条件(温度:22℃±2℃,湿度:50%±5%,明暗:光/暗循环(light/dark cycle)12小时)适应一周后使用。
给正常组提供AIN-93G(Nor;Diet D10012G,Research Diets,Inc.,NewBrunswick,NJ,USA),给高脂肪饮食组提供购自减肥(Diet)公司的60%高脂肪饮食(high-fat diet,HFD;Diet 12492,Research Diets,Inc.,New Brunswick,NJ,USA)。
【1-2.向小鼠给药肥胖及试验物质】
实验采用随机区组设计(变量因子和参数因子的混合模型),将C57BL/J雄性小鼠分为六组,每组10只,进行实验。
如下表1所示,分为将给药正常饮食的正常组、给药高脂肪饮食的对照组及进行高脂肪饮食并将实施例分别给药100mg/kg、200mg/kg及400mg/kg的组进行实验。
【表1】
向没有给药试样的正常饮食组的正常组及高脂肪饮食组的对照组给药相同量(0.2ml/小鼠/天)的生理盐水。
实验结束前一天,对六个实验组的60只小鼠禁食12小时,然后在实验结束当天,对小鼠进行麻醉并从眼眶采血,采集的血液经血浆分离并保存在-80℃冷冻室里。并且,取出小鼠的脂肪组织和脏器进行称重。
【1-3.小鼠的体重变化、饮食摄入及饮食效率】
在口服实施例8周的同时,每周规定时间测定体重变化及饮食摄入量。调查了总增重量及日平均增重量(总增重量/天(Total body weight gain/days))。并且,在调查饮食摄入量(总食物摄入量/天(Total food intake/days))后,根据下述计算式1计算饮食效率,其结果如表2所示。
【计算式1】
饮食效率=总增重量(Total weight gain)/总饮食摄入量(Total food intake)×100
【表2】
统计学显著性比较对照组*:p<0.05
在高脂肪饮食诱导的小鼠中测定实施例的抗肥胖效果,结果,在体重增长量中,与正常组4.50±1.28(P<0.001)相比,高脂肪饮食对照组为12.66±2.26,表现出显著的增加。
然而,当实施例以100mg/kg给药时为9.38±2.55(P<0.05),当实施例以200mg/kg给药时为9.55±2.64(P<0.05),表现出显著的下降。
与给药正常饮食的正常组相比,给药高脂肪饮食的高脂肪饮食组的饮食摄入量降低。然而,高脂肪饮食组之间的饮食摄入量没有显著差异。
【实验例2.血液生化检查】
将实验结束后获得的血液以3000rpm转速离心20分钟分离血清以进行生化指标成分分析。
用分离的血清测定作为脂质含量指标的总胆固醇(Total cholesterol)及中性脂肪(甘油三酯(Triglyceride)),其结果如表3、图1a及图1b所示。
【表3】
统计学显著性比较对照组*:p<0.05,**:p<0.01
比较各实验组的血液总胆固醇含量的结果,测得正常组为96.17mg/dL及对照组为139.1mg/dL。这意味着由高脂肪饮食给药时总胆固醇水平会增加。
然而,当实施例以100mg/kg给药时为110.7mg/dL,当实施例以200mg/kg给药时为114.6mg/dL,当实施例以400mg/kg给药时为122.43mg/dL。
尤其,在实施例的100mg/kg及200mg/kg给药组中,表现出显著的降低。
并且,对各实验组的血液中性脂肪含量进行分析的结果,测得正常组为132.3mg/dL及对照组为235.8mg/dL。这意味着由高脂肪饮食给药时血液中性脂肪含量会增加。
然而,当实施例以100mg/kg给药时为185.1mg/dL,当实施例以200mg/kg给药时为182.3mg/dL,当实施例以400mg/kg给药时为209.8mg/dL。
由此确认,与对照组相比,实施例100mg/kg及200mg/kg给药组表现出显著的降低。
【实验例3.小鼠脂肪组织中脂肪含量的测定】
为了测定给药实施例后对脂肪组织的影响,测定了腹部周围和肾脏周围的总脂肪重量。测定脂肪组织的抗肥胖作用并将正常饮食组和高脂饮食组的腹部脂肪组织量示出在表4和图2a中。并且,测定肾脏周围的总脂肪重量的结果如表4和图2B所示。
【表4】
统计学显著性比较对照组*:p<0.05
测定各组的腹部周围脂肪重量结果,高脂肪饮食组的腹部脂肪组织为6.13±0.10(g/100g BW),比正常组腹部脂肪组织测定值1.89±0.08(g/100g BW)高出约2.13倍至5.67倍。
然而,当实施例以100mg/kg给药时为5.04±0.10(g/100g BW),当实施例以200mg/kg给药时为5.06±0.11(g/100g BW),当实施例以400mg/kg给药时为5.83±0.11(g/100gBW)。
由此确认,与对照组相比,在实施例100mg/kg及200mg/kg给药组表现出显著的降低。
并且,对各组的肾脏周围脂肪重量进行测定,结果,高脂肪饮食组的腹部脂肪组织为2.73±0.06(g/100g BW),高于正常组腹部脂肪组织的测定值0.68±0.05(g/100g BW)。
然而,当实施例以100mg/kg给药时为2.27±0.02(g/100g BW),当实施例以200mg/kg给药时为2.29±0.03(g/100g BW),当实施例以400mg/kg给药时为2.37±0.03(g/100gBW)。
由此确认,与对照组相比,在实施例100mg/kg及200mg/kg给药组表现出显著的降低。
【实验例4.中性脂肪合成相关蛋白质表达的评价】
在由高脂肪饮食诱导的肥胖动物模型中评价与实施例的中性脂肪合成相关蛋白质的表达。采集脂肪组织并进行蛋白质印迹(Western blot)以测定肥胖相关基因PPARr、GLUT4的表达水平。并且,使用在大多数细胞中表达的管家基因(housekeeping gene)肌动蛋白(Actin)测定蛋白质的表达水平,确认了在蛋白质印迹过程中实验了相同的量。中性脂肪合成相关蛋白质的表达结果如图3所示。
如图3所示,与正常组相比,高脂肪饮食组的对照组的中性脂肪合成相关蛋白的表达量明显增加。但是,在给药实施例的情况下,可以确认中性脂肪合成相关蛋白质的表达量降低。
尤其,在实施例100mg/kg及200mg/kg给药组中显示出与正常组相似的表达水平,表现出显著的降低。
由此确认,实施例对改善代谢性疾病有功效。
【产业上的可利用性】
本发明涉及用于预防、改善或治疗肥胖的组合物。
Claims (8)
1.用于预防或改善肥胖的食品组合物,其包含选自由白首乌、糙苏及当归组成的组中的一种以上提取物。
2.根据权利要求1所述的食品组合物,其中所述肥胖是饮食摄取引起的肥胖,神经性胃炎性肥胖、麸质过度肥胖、静脉循环障碍肥胖或代谢性肥胖。
3.根据权利要求2所述的食品组合物,其中所述代谢性肥胖引起糖尿病、高脂血症、心脏病、中风、动脉硬化症或脂肪肝。
4.根据权利要求1所述的食品组合物,其中所述提取物是用选自由水及碳原子数为1个至4个的直链或支链醇组成的组中的一种以上溶剂提取得到的粗提取物。
5.用于预防或治疗肥胖的药物组合物,其包含选自由白首乌、糙苏及当归组成的组中的一种以上提取物。
6.根据权利要求5所述的药物组合物,其中所述肥胖是饮食摄取引起的肥胖、神经性胃炎性肥胖、麸质过度肥胖、静脉循环障碍肥胖或代谢性肥胖。
7.根据权利要求6所述的药物组合物,其中所述代谢性肥胖引起糖尿病、高脂血症、心脏病、中风、动脉硬化症或脂肪肝。
8.根据权利要求5所述的药物组合物,其中所述提取物是用选自由水及碳原子数为1个至4个的直链或支链醇组成的组中的一种以上溶剂提取得到的粗提取物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200068218A KR102501310B1 (ko) | 2020-06-05 | 2020-06-05 | 항비만용 조성물 |
KR10-2020-0068218 | 2020-06-05 | ||
PCT/KR2021/006436 WO2021246703A1 (ko) | 2020-06-05 | 2021-05-24 | 항비만용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115915971A true CN115915971A (zh) | 2023-04-04 |
Family
ID=78831567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180042423.8A Pending CN115915971A (zh) | 2020-06-05 | 2021-05-24 | 抗肥胖用组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230201289A1 (zh) |
EP (1) | EP4162813A4 (zh) |
KR (2) | KR102501310B1 (zh) |
CN (1) | CN115915971A (zh) |
WO (1) | WO2021246703A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050111658A (ko) * | 2004-05-21 | 2005-11-28 | 주식회사 엠디바이오알파 | 당귀 추출물을 유효성분으로 함유하는 비만 치료제 |
KR20110114940A (ko) * | 2010-04-14 | 2011-10-20 | 사단법인 진안군친환경홍삼한방산업클러스터사업단 | 속단 추출물을 유효성분으로 포함하는 지질 관련 심혈관 질환 또는 비만의 예방 및 치료용 조성물 |
KR20110125958A (ko) * | 2010-05-14 | 2011-11-22 | 한국식품연구원 | 유효성분으로 백하수오 에탄올 추출물을 포함하는 혈중 콜레스테롤 저하용 조성물 |
CN102697057A (zh) * | 2012-06-26 | 2012-10-03 | 陈庆忠 | 一种具有减肥、排毒、降糖、降脂、降压功能的营养餐 |
KR20190106587A (ko) * | 2018-03-09 | 2019-09-18 | 경북대학교 산학협력단 | 한속단 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100232671B1 (ko) * | 1997-07-25 | 2000-02-01 | 김이현 | 부인과 질환 및 여성비만 치료를 위한 조성물의 제조방법 |
WO2019083321A2 (ko) * | 2017-10-27 | 2019-05-02 | 주식회사 내츄럴엔도텍 | 항산화, 항염 또는 파골세포 분화 억제용 조성물 |
KR101969236B1 (ko) * | 2017-11-29 | 2019-07-22 | 극동대학교 산학협력단 | 비만예방 한약으로 만든 젤리 및 그 제조방법 |
KR102204831B1 (ko) | 2018-12-05 | 2021-01-19 | (주)유비엔 | 스마트 팜용 모터 일체형 온실 환기창 개폐용 구동기 |
-
2020
- 2020-06-05 KR KR1020200068218A patent/KR102501310B1/ko active IP Right Grant
-
2021
- 2021-05-24 US US18/008,219 patent/US20230201289A1/en active Pending
- 2021-05-24 CN CN202180042423.8A patent/CN115915971A/zh active Pending
- 2021-05-24 WO PCT/KR2021/006436 patent/WO2021246703A1/ko active Application Filing
- 2021-05-24 EP EP21817792.1A patent/EP4162813A4/en active Pending
-
2023
- 2023-01-17 KR KR1020230007018A patent/KR20230016241A/ko not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050111658A (ko) * | 2004-05-21 | 2005-11-28 | 주식회사 엠디바이오알파 | 당귀 추출물을 유효성분으로 함유하는 비만 치료제 |
KR20110114940A (ko) * | 2010-04-14 | 2011-10-20 | 사단법인 진안군친환경홍삼한방산업클러스터사업단 | 속단 추출물을 유효성분으로 포함하는 지질 관련 심혈관 질환 또는 비만의 예방 및 치료용 조성물 |
KR20110125958A (ko) * | 2010-05-14 | 2011-11-22 | 한국식품연구원 | 유효성분으로 백하수오 에탄올 추출물을 포함하는 혈중 콜레스테롤 저하용 조성물 |
CN102697057A (zh) * | 2012-06-26 | 2012-10-03 | 陈庆忠 | 一种具有减肥、排毒、降糖、降脂、降压功能的营养餐 |
KR20190106587A (ko) * | 2018-03-09 | 2019-09-18 | 경북대학교 산학협력단 | 한속단 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20230201289A1 (en) | 2023-06-29 |
KR20210151420A (ko) | 2021-12-14 |
WO2021246703A1 (ko) | 2021-12-09 |
KR20230016241A (ko) | 2023-02-01 |
KR102501310B1 (ko) | 2023-02-21 |
EP4162813A1 (en) | 2023-04-12 |
EP4162813A4 (en) | 2023-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645385B1 (ko) | 비만 억제용 조성물 | |
CN101243882B (zh) | 具有降血脂功能的保健食品及其制备方法 | |
CN110604773B (zh) | 调节脂代谢紊乱的组合物及其制备方法和用途 | |
CN103432192B (zh) | 一种具有减肥作用的组合物 | |
CN112970992A (zh) | 一种适合糖尿病人的固体饮料及制作方法 | |
CN106177432A (zh) | 一种包含青钱柳叶、桑叶、绿茶和玉竹的保健组合物 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
CN106579392A (zh) | 一种缓解延迟性肌肉酸痛的组合物 | |
KR101385657B1 (ko) | 생약 추출물을 포함하는 남성 발기부전 예방 또는 치료용 조성물 및 건강 기능성 식품 | |
JP2003171303A (ja) | 特定植物含有組成物と該組成物を有効成分とする医薬品と保健用食品 | |
KR20090099974A (ko) | 상엽 추출물을 유효성분으로 함유하는 고지혈증 또는비만의 예방 및 치료용 조성물 | |
KR101032685B1 (ko) | 항비만용 조성물 | |
CN115915971A (zh) | 抗肥胖用组合物 | |
KR20130018432A (ko) | 생약 추출물을 포함하는 남성 발기부전 예방 또는 치료용 조성물 및 건강 기능성 식품 | |
EP4162814A1 (en) | Composition for fatigue recovery | |
KR100504124B1 (ko) | 비만억제용 조성물 | |
KR101693573B1 (ko) | 갱년기 증상의 예방 또는 치료 효과가 있는 약제학적 조성물 및 그 제조방법 | |
CN102579713B (zh) | 治疗儿童肥胖症的中药及制备方法 | |
KR100473529B1 (ko) | 순기산 생약 복합제 추출물을 유효성분으로 함유하는당뇨병 예방 및 치료용 조성물 | |
KR20230092650A (ko) | 율피 추출물을 포함하는 여성 갱년기 증상 예방 또는 개선용 조성물 | |
KR100573590B1 (ko) | 비만치료ㆍ억제용 생약 조성물 | |
KR100450055B1 (ko) | 두과 식물을 주성분으로 함유하는 체질개선용 식품 조성물및 그로부터 제조되는 식품 | |
KR100478150B1 (ko) | 생약 복합제 추출물을 유효성분으로 함유하는 당뇨병 예방용 건강보조식품 | |
KR20210076885A (ko) | 변비 개선 및 항비만에 도움이 되는 한방추출물 및 이의 제조 방법, 한방추출물을 이용한 곤약 젤리 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |